Retatrutide
An investigational triple agonist (GIP/GLP-1/glucagon) from Eli Lilly. Not FDA-approved. In Phase III TRIUMPH-1 (NEJM, September 2026) the 12 mg dose produced 25.0% mean weight loss at 80 weeks, and TRIUMPH-2 (Lancet, September 2026) showed up to 18.8% in adults with obesity and type 2 diabetes. Lilly plans to file with the FDA in Q1 2027.
Retatrutide is an experimental Eli Lilly drug that acts on three hormones (GIP, GLP-1, and glucagon) to reduce weight and improve metabolism. In trials it produced the largest weight loss of any obesity drug still in development — about 24%. It is not FDA-approved yet and is still in late-stage testing, so its long-term safety isn't fully known.
What is Retatrutide?
Retatrutide is an investigational triple hormone receptor agonist developed by Eli Lilly, targeting GIP, GLP-1, and glucagon receptors simultaneously. It is not FDA-approved and is currently in Phase III clinical development (the TRIUMPH program). Phase II trials showed up to 24.2% weight loss at 48 weeks. Phase III TRIUMPH-4 (December 2025 topline, adults with obesity and knee osteoarthritis) reported 28.7% mean weight loss at 12 mg over 68 weeks (about 71 lb; efficacy estimand — 23.7%, about 60 lb, by treatment-regimen estimand), and the two pivotal obesity trials were published on 29 September 2026: TRIUMPH-1 in the New England Journal of Medicine (2,339 adults without diabetes; -17.6%, -23.7%, and -25.0% at 4, 9, and 12 mg vs -3.9% on placebo at 80 weeks) and TRIUMPH-2 in the Lancet (1,152 adults with obesity and type 2 diabetes; -11.9%, -16.8%, and -18.8% vs -5.1%). A third pivotal trial, TRIUMPH-3 (severe obesity with established cardiovascular disease), reported up to 22.6% weight loss at 80 weeks in July 2026 topline results. Lilly plans to submit retatrutide to the FDA in Q1 2027, so approval is unlikely before 2027.
What Retatrutide Is Investigated For
Retatrutide is investigated primarily for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH), and the strongest evidence to date is for weight loss — Phase 2 trials produced 24.2% mean weight loss at 48 weeks (the largest obesity-drug weight loss ever recorded at that time) and the Phase 3 TRIUMPH-4 readout in December 2025 reported 28.7% at 12 mg over 68 weeks in adults with obesity and knee osteoarthritis (efficacy estimand; 23.7% by treatment-regimen estimand). The first published Phase 3 primary readout arrived in June 2026 with TRANSCEND-T2D-1 in the Lancet (PMID 42250575), moving retatrutide from press-release Phase 3 into a genuine peer-reviewed Phase 3 evidence base for glycemic control in T2D. The two pivotal obesity trials followed on 29 September 2026. TRIUMPH-1 (NEJM, PMID 42814954; 2,339 adults with obesity and no diabetes) produced mean weight loss of 17.6%, 23.7%, and 25.0% at 4, 9, and 12 mg versus 3.9% on placebo at 80 weeks (treatment-regimen estimand), and its substudies also showed less knee-osteoarthritis pain and fewer sleep-apnea events. TRIUMPH-2 (Lancet, PMID 42810372; 1,152 adults with obesity and type 2 diabetes) produced 11.9%, 16.8%, and 18.8% versus 5.1% on placebo, and Lilly reported HbA1c reductions of 1.4–1.6 points versus 0.2 on placebo, with about 79% of participants on 9 or 12 mg reaching an HbA1c of 6.5% or lower. TRIUMPH-3 (topline July 2026, not yet published), in adults with severe obesity and established cardiovascular disease, reported 21.6% and 22.6% weight loss at 9 and 12 mg versus 3.2% on placebo (efficacy estimand); MACE events were fewer than anticipated, so its cardiovascular hazard ratios were inconclusive. A Phase 2a substudy in adults with MASLD (Sanyal et al., Nat Med 2024) also showed relative liver-fat reductions of about 81–82% at 24 weeks on 8 and 12 mg, with most participants reaching normal liver fat; liver fat was measured by MRI (MRI-PDFF), not biopsy, so that trial says nothing yet about histologic MASH resolution. A T2D Phase 2 trial reported HbA1c reductions up to 2.02%, and a 2026 High Blood Press Cardiovasc Prev meta-analysis (PMID 42371360) confirmed favorable effects on blood pressure and lipid levels. The honest caveat is that retatrutide is not yet FDA-approved — Lilly opened it to US compassionate use in mid-2026 (BMJ, PMID 42567543) and plans to file with the FDA in Q1 2027, cardiovascular-outcome and TRANSCEND-CKD results are still outstanding, long-term safety beyond roughly two years is uncharacterized, Phase 3 surfaced a dose-related dysesthesia (abnormal skin sensation) signal, and the glucagon component introduces heart-rate and glycemic signals that pure GLP-1 and GIP/GLP-1 agonists do not share. Cross-trial comparisons favoring retatrutide over tirzepatide should be read with that methodological caution in mind.
History & Discovery
Retatrutide (LY3437943) was developed by Eli Lilly as the first triple agonist to reach late-stage obesity trials, simultaneously activating the GIP, GLP-1, and glucagon receptors from a single 39-amino-acid molecule. Its scientific premise built on the preclinical and early clinical success of tirzepatide (dual GIP/GLP-1) and on longstanding interest in glucagon-receptor agonism as a thermogenic and hepatic-fat-mobilizing mechanism — an effect first demonstrated decades ago but difficult to harness therapeutically because of glucagon's hyperglycemic effect. By balancing glucagon-receptor activation against the glucose-lowering effects of GIP and GLP-1, retatrutide's molecular design aims to capture glucagon's energy-expenditure benefit without destabilizing glycemic control. The first-in-patient Phase 1b trial was published in 2022, and the landmark Phase 2 trial in NEJM (2023) reported up to 24.2% weight loss at 48 weeks at the 12 mg dose — the largest obesity-drug weight loss recorded at that time. Lilly's Phase 3 TRIUMPH program began in 2023 and encompasses at least 7 trials; TRIUMPH-4 headline results reported in December 2025 showed 28.7% mean weight loss (efficacy estimand; 23.7% treatment-regimen) at the 12 mg dose over 68 weeks in adults with obesity and knee osteoarthritis (an average of about 71 lb). The first Phase 3 primary readout entered the peer-reviewed literature in June 2026 when TRANSCEND-T2D-1 was published in the Lancet (PMID 42250575), demonstrating retatrutide's efficacy and safety in adults with type 2 diabetes inadequately controlled by diet and exercise. In mid-2026 Lilly also opened retatrutide to US compassionate use following extensive public attention (BMJ, PMID 42567543) — a substantive access change from the previous trial-participant-only pathway, though not equivalent to full FDA approval. Lilly announced TRIUMPH-1 topline results on 21 May 2026 (presented at ADA 2026 in June) and TRIUMPH-2 and TRIUMPH-3 toplines on 23 July 2026, and on 29 September 2026 the two pivotal obesity trials were published together: TRIUMPH-1 in NEJM (PMID 42814954; -25.0% at 12 mg vs -3.9% placebo over 80 weeks in adults without diabetes) and TRIUMPH-2 in the Lancet (PMID 42810372; -18.8% vs -5.1% in adults with obesity and type 2 diabetes), with TRIUMPH-2 also presented at EASD 2026 in Milan. Lilly said it plans to submit retatrutide to the FDA in Q1 2027. TRANSCEND-CKD (Nephrol Dial Transplant, PMID 41160422) and the cardiovascular-outcome trials are still running.
How It Works
Retatrutide activates three hormone receptors at once: GLP-1 and GIP reduce appetite, while glucagon tells your body to burn more energy and fat. This three-pronged approach produces the most weight loss ever seen in a clinical trial.
Retatrutide is a 39-amino acid peptide with agonist activity at GIPR, GLP-1R, and GCGR. GLP-1R and GIPR activation suppress appetite through hypothalamic and brainstem circuits. GCGR activation increases hepatic fatty acid oxidation, energy expenditure, and thermogenesis. The glucagon component also reduces hepatic steatosis, making it promising for NASH. The three pathways produce complementary and potentially synergistic metabolic effects. A 2026 J Clin Endocrinol Metab metabolomics substudy (Pearson et al., n=495) provided the first mechanistic decomposition of retatrutide's weight-loss signature in humans — higher doses drove a coordinated shift in fatty-acid oxidation markers (3-hydroxybutyrate, acetylcarnitine, free carnitine, long-chain acylcarnitines) plus reductions in insulin-resistance markers (BCAAs, 2-aminoadipic acid, urate); mediation analysis attributed approximately 23.2% of the weight-reduction effect in non-T2D participants to the acylcarnitine cluster alone, supporting the glucagon-receptor-driven hepatic fat oxidation hypothesis at the metabolite level.
Evidence Snapshot
Human Clinical Evidence
Strong and now peer-reviewed at Phase 3. Phase II showed 24.2% weight loss at 48 weeks. Phase III TRIUMPH-4 reported 28.7% at 12 mg (efficacy estimand; 23.7% treatment-regimen; 68 weeks, knee osteoarthritis). Lancet TRANSCEND-T2D-1 (June 2026, PMID 42250575) delivered the first peer-reviewed Phase 3 primary readout. TRIUMPH-1 (NEJM, 29 Sep 2026, PMID 42814954) showed -25.0% at 12 mg vs -3.9% placebo at 80 weeks in 2,339 adults without diabetes, and TRIUMPH-2 (Lancet, 29 Sep 2026, PMID 42810372) showed -18.8% vs -5.1% in 1,152 adults with obesity and T2D (treatment-regimen estimand). Cardiovascular-outcome and CKD trials still running; US compassionate use opened mid-2026; FDA submission planned for Q1 2027. Not yet FDA-approved.
Animal / Preclinical
Strong. Triple agonism concept well-supported in preclinical models.
Mechanistic Rationale
Strong. All three receptor pathways are individually well-characterized.
Research Gaps & Open Questions
What the current literature has not yet settled about Retatrutide:
- 01Hard-outcome Phase 3 data — the pivotal weight-loss trials are now peer-reviewed (TRANSCEND-T2D-1, Lancet June 2026, PMID 42250575; TRIUMPH-1, NEJM, PMID 42814954, including its knee-osteoarthritis and sleep-apnea substudies; TRIUMPH-2, Lancet, PMID 42810372, both September 2026), but hard-outcome data are still outstanding. TRIUMPH-3 (topline July 2026, adults with obesity and established cardiovascular disease) recorded fewer MACE events than anticipated, giving inconclusive hazard ratios (MACE-5 HR 0.82, 95% CI 0.55–1.22; MACE-3 HR 1.12, 0.64–1.96). The dedicated cardiovascular and kidney outcomes trial (NCT06383390) has an estimated primary completion in 2029, and MASH and CKD results (the TRANSCEND-CKD design paper is at PMID 41160422) are also pending.
- 02Long-term safety beyond 88 weeks — all published and planned trials end at or before that duration; chronic multi-year safety data is not yet available.
- 03Glucagon-specific and other safety signals — heart rate elevation, modest fasting glucose effects, and possible hepatic effects specific to glucagon-receptor activation require continued characterization at the 12 mg dose over longer exposure windows, and the dose-related dysesthesia seen in TRIUMPH-1 and TRIUMPH-2 (and the hypotension seen in TRIUMPH-2) has no established mechanism yet. A 2026 Diabetes Obes Metab study (PMID 42608321) characterized retatrutide-associated changes in cardiovascular risk biomarkers, and a 2026 High Blood Press Cardiovasc Prev meta-analysis (PMID 42371360) confirmed favorable BP and lipid effects across the trial base — both partially softening the CV concern, though hard cardiovascular endpoint data remains outstanding.
- 04Withdrawal and weight-regain kinetics — no published Phase 3 withdrawal arm data comparable to SURMOUNT-4 or STEP-1 extension (the TRIUMPH-6 maintenance trial, NCT06859268, is running); timing and magnitude of regain after discontinuation is inferred rather than measured.
- 05Body composition across the dose range — whether the greater absolute weight loss at 12 mg is accompanied by disproportionate lean mass loss relative to tirzepatide or semaglutide remains under study.
- 06Head-to-head comparison with tirzepatide at maximal dose — no direct trial comparison has been completed (TRIUMPH-5, NCT06662383, compares the two in adults with obesity, with estimated primary completion in late 2026), so relative efficacy and tolerability judgments rely on cross-trial indirect comparisons with their inherent limitations.
Forms & Administration
Weekly SC injection. Phase II doses: 1-12mg weekly. Dose titration protocol similar to other incretin drugs. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Retatrutide is investigational; doses below reflect trial protocols, not FDA labeling. The Phase 2 trial (Jastreboff et al., NEJM 2023) evaluated 1, 4, 8, and 12 mg weekly maintenance doses following gradual titration starting at 2 mg. The Phase 3 TRIUMPH-1 and TRIUMPH-2 trials used maintenance doses of 4, 9, and 12 mg weekly (TRIUMPH-4 tested 9 and 12 mg). In Phase 2, titration began at 2 mg weekly and escalated at 4-week intervals (2 → 4 → 8 → 12 mg); Phase 3 also escalates in 4-week steps, analogous to the tirzepatide schedule, to manage GI tolerability.
Frequency
Once weekly by subcutaneous injection in all published and ongoing trials. Trial protocols permit injection on any day of the week, same day each week.
Timing Considerations
Time of day
Once-weekly: same day each week, consistent time of day. The long half-life makes hour-of-day largely irrelevant.
Relative to meals
With or without food.
Relative to exercise
Unrelated to training.
Cycle Length
Retatrutide has not been approved or released for clinical use, so 'protocol length' outside trials is not defined. Phase 2 ran 48 weeks; Phase 3 TRIUMPH trials run 48–88 weeks depending on indication. If retatrutide reaches approval for obesity, the anticipated usage pattern — based on mechanism and on the semaglutide/tirzepatide precedent — will be indefinite chronic use, with substantial weight regain on discontinuation. No withdrawal-specific trial data is yet published.
Protocol Notes
Retatrutide is not FDA-approved. Legal access is limited to Lilly-sponsored clinical trials and, since mid-2026, Lilly's US compassionate-use program; participants receive investigational drug product through the sponsor. Compounded retatrutide has begun appearing on grey-market and research-chemical websites, but because retatrutide is an unapproved investigational drug, compounding is not authorized and products marketed this way carry unresolved regulatory and product-quality concerns. GI tolerability in Phase 2 was broadly comparable to tirzepatide, with dose-dependent nausea, vomiting, and diarrhea concentrating at titration steps; the glucagon component also produces a dose-dependent rise in resting heart rate that peaked around week 24 and then declined in Phase 2 (a 2026 meta-analysis put the average increase at about 3.5 bpm over placebo), which is being monitored in Phase 3.
Retatrutide is not FDA-approved and is available only through Lilly-sponsored clinical trials or Lilly's US compassionate-use program. Any non-trial sourcing involves unapproved investigational drug product and is not a medically or legally validated pathway.
Timeline of Effects
Onset
In the Phase 2 trial, weight-loss separation from placebo was visible by week 4 and clearly established by week 12. Appetite suppression is reported within the first 1–2 weeks of dosing, consistent with the GIP/GLP-1 components of the mechanism. HbA1c reductions in type 2 diabetes participants reached statistical separation from placebo by week 8.
Peak Effect
At 48 weeks in the NEJM Phase 2 trial, participants at the 12 mg dose had lost 24.2% of body weight with no clear plateau — the curve was still sloping downward at trial end, suggesting additional weight loss would have accrued with extended exposure. In the type 2 diabetes Phase 2 trial, HbA1c reduction at 36 weeks reached 2.02 percentage points at the 12 mg dose. Phase 3 has now extended the picture: in TRIUMPH-1, mean weight loss at 80 weeks was 25.0% at 12 mg (treatment-regimen estimand; Lilly's efficacy-estimand figure was 28.3%), and in TRIUMPH-2, which enrolled people with type 2 diabetes, it was 18.8% at 12 mg, with HbA1c down 1.4–1.6 points. Long-term plateau data beyond about two years have not been published.
After Discontinuation
No published withdrawal data exist for retatrutide as of October 2026 (the TRIUMPH-6 maintenance trial is still running). Based on mechanistic parallels to semaglutide and tirzepatide — both of which show roughly two-thirds weight regain within a year of discontinuation — the working assumption in the field is that retatrutide will behave similarly, with weight regain proportional to the weight lost. The glucagon component's thermogenic effect is also presumed to reverse on discontinuation. These assumptions await trial confirmation.
Monitoring & Measurement
Bloodwork & Labs
- •HbA1c, fasting glucose, fasting insulin (HOMA-IR)
- •Lipid panel — triglycerides especially, because glucagon agonism shifts hepatic lipid handling in a way GLP-1 alone does not
- •ALT and AST — hepatic fat reduction is part of the mechanism; trend matters more than any single value
- •Lipase and amylase at baseline
- •Uric acid — glucagon agonism can nudge this upward in susceptible patients
Functional & Performance Tests
- •Body weight (same scale, weekly)
- •Waist circumference
- •Home blood pressure cuff
- •Resting heart rate (wearable) — this is the most important functional marker for retatrutide
- •DEXA scan if accessible
When to Test
Baseline, 12 weeks, 24 weeks; heart rate tracked weekly at home from the start.
Interpretation & Notes
Phase 2 data showed ~24% body weight loss at 12 mg by week 48 — the largest published result in the class. The glucagon-receptor agonism adds a thermogenic and hepatic-lipid benefit on top of GLP-1/GIP, but also produces a dose-dependent rise in resting heart rate that peaked around week 24 and then declined in Phase 2 (a 2026 meta-analysis put the average increase at about 3.5 bpm over placebo). That's the tradeoff most worth monitoring: check resting HR at home weekly, and flag a sustained rise above 10 bpm to a clinician before escalating dose. As of 2026 retatrutide is still investigational — not FDA-approved — so source verification, purity testing, and clinical supervision matter more here than with approved analogs. Standard metabolic panels are widely available direct-to-consumer; ALT/AST and uric acid are included in routine comprehensive metabolic panels.
Common Questions
Why add glucagon to GIP/GLP-1?
Glucagon receptor activation increases energy expenditure and hepatic fat oxidation. Combined with the appetite suppression from GIP/GLP-1, this creates both reduced calorie intake AND increased calorie burning, potentially explaining the superior weight loss.
When will retatrutide be FDA-approved?
Retatrutide is not FDA-approved as of October 2026. The core Phase 3 obesity data are now published — TRIUMPH-1 in NEJM and TRIUMPH-2 in the Lancet, both on 29 September 2026 — and Lilly has said it plans to submit retatrutide to the FDA in Q1 2027. A standard review would put a decision in 2027 at the earliest, later if the review is extended. Cardiovascular-outcome and kidney (TRANSCEND-CKD) trials are still running.
Does retatrutide work for people with type 2 diabetes?
Yes, though weight loss is smaller than in people without diabetes, as with every drug in the class. In TRIUMPH-2 (Lancet, September 2026; 1,152 adults with obesity and type 2 diabetes), mean weight loss at 80 weeks was 11.9%, 16.8%, and 18.8% at 4, 9, and 12 mg versus 5.1% on placebo (treatment-regimen estimand). Lilly reported HbA1c reductions of 1.4–1.6 points from a baseline near 7.7%, versus 0.2 on placebo, and about 79% of participants on 9 or 12 mg reached an HbA1c of 6.5% or lower. Permanent discontinuation due to adverse events or death was 4% at 4 mg, 12% at 9 mg, and 8% at 12 mg versus 5% on placebo. The separate TRANSCEND-T2D program tests retatrutide mainly for glucose control.
How does retatrutide compare to tirzepatide?
Cross-trial comparisons favor retatrutide at the top dose — 25.0% weight loss at 12 mg over 80 weeks in Phase 3 TRIUMPH-1 vs. roughly 20-22% for tirzepatide at its maximum dose — but no head-to-head trial has been completed, so the comparison carries the usual indirect-comparison caveats. Mechanistically, retatrutide adds glucagon-receptor agonism, which drives extra hepatic fat oxidation and thermogenesis but also produces a modestly larger resting heart-rate elevation (in Phase 2, a dose-dependent rise that peaked around week 24 and then declined; a 2026 meta-analysis pooled it at about 3.5 bpm over placebo, versus about 2 bpm for tirzepatide) and a different glycemic profile than tirzepatide's dual GIP/GLP-1 action.
Who Retatrutide Is NOT For
- •Personal or family history of medullary thyroid carcinoma (MTC) — the incretin-class boxed warning is expected to apply to retatrutide based on shared rodent C-cell tumor findings in the class.
- •Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — same mechanistic concern as MTC.
- •Active pancreatitis or history of recurrent pancreatitis — GLP-1 class pancreatitis signal applies; retatrutide trials excluded participants with prior pancreatitis.
- •Pregnancy — investigational drug, no reproductive toxicology data in humans; trial protocols exclude pregnant and breastfeeding participants.
- •Breastfeeding — no data on transfer into milk or infant effects.
- •Severe gastroparesis or significant gastrointestinal motility disorders — delayed gastric emptying from GLP-1 component can worsen symptoms.
- •Pediatric use (under 18) — no pediatric studies; every retatrutide trial registered on ClinicalTrials.gov enrolls adults only as of October 2026.
- •Active or decompensated type 1 diabetes — the glucagon component's effect on glycemic control in T1D is inadequately characterized; T1D patients have been excluded from trials.
- •Poorly controlled cardiovascular disease or recent MI — TRIUMPH trials have specific cardiovascular exclusion criteria, and retatrutide's heart-rate effect is larger than tirzepatide's, warranting caution.
Drug & Supplement Interactions
Clinical drug interaction data for retatrutide is limited to trial-protocol observations rather than dedicated pharmacokinetic studies. Based on mechanism, the expected interaction domains parallel tirzepatide: combination with insulin or insulin secretagogues (sulfonylureas, meglitinides) raises hypoglycemia risk and requires downward dose adjustment of those agents; delayed gastric emptying may alter absorption of orally administered drugs, particularly relevant for warfarin (INR monitoring) and levothyroxine (TSH monitoring). The glucagon component introduces a distinct consideration: glucagon-receptor activation can modestly elevate fasting glucose and HbA1c at higher doses, so patients on anti-diabetic therapy need tighter glycemic monitoring than on pure GLP-1 or GIP/GLP-1 agonists. Retatrutide has shown small dose-dependent heart rate elevations (in Phase 2 they peaked around week 24 and then declined; a 2026 meta-analysis put the average increase at about 3.5 bpm over placebo), which may compound with beta-agonists, thyroid-replacement, stimulants, and sympathomimetics. Because retatrutide is not yet approved, no definitive prescribing-information interaction tables exist; the discussion here is mechanism-inferred and should not be treated as clinically validated guidance.
Safety Profile
Common Side Effects
Cautions
- • Not yet FDA-approved
- • Cardiovascular-outcome and kidney Phase III trials still running
- • Dysesthesia (abnormal skin sensation) and hypotension were more frequent than placebo in Phase III — in TRIUMPH-2, dysesthesia 4–7% vs 1% and hypotension 1–6% vs <1%
- • Glucagon component may affect blood sugar differently
- • Long-term safety unknown
What We Don't Know
Phase III cardiovascular outcomes, long-term safety, and optimal dosing are still being determined.
Legal Status
United States
Retatrutide is not FDA-approved for any indication. It is an investigational drug under Eli Lilly's IND. As of mid-2026, access expanded from trial-participant-only to include US compassionate use (BMJ, PMID 42567543), a limited-access expansion that followed extensive public attention around the program. Broad clinical access remains through the ongoing TRIUMPH and TRANSCEND Phase 3 program. With TRIUMPH-1 (NEJM) and TRIUMPH-2 (Lancet) published in September 2026, Lilly has said it plans to submit retatrutide to the FDA in Q1 2027, which puts any approval in 2027 at the earliest. There is no legal compounding pathway for retatrutide in the US, since compounding under 503A requires either an FDA-approved reference product (which does not exist) or a validated bulk drug substance list entry (which does not apply here). Research-chemical suppliers advertising retatrutide are not operating within an approved clinical or compounding framework — a 2026 Cureus case report (PMID 42669023) documented online-sourced retatrutide precipitating impending diabetic ketoacidosis in a type 1 diabetes patient during concurrent Shigella gastroenteritis, illustrating the real risks of grey-market sourcing combined with disallowed populations.
International
No major regulator — EMA, UK MHRA, Health Canada, Australia's TGA — has authorized retatrutide as a medicine. Lilly's TRIUMPH program has sites in multiple jurisdictions, so trial access varies by country. Personal-use importation of research-chemical retatrutide is prohibited or restricted in most jurisdictions.
Sports & Competition
Retatrutide is not named on the WADA Prohibited List (2026 list, or the 2027 list in force from January 1, 2027), but WADA's S0 category prohibits at all times any pharmacological substance not covered elsewhere on the List 'with no current approval by any governmental regulatory health authority for human therapeutic use', including drugs in clinical development. That covers retatrutide until a regulator approves it. Athletes subject to the WADA Code should treat retatrutide as prohibited in and out of competition.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Retatrutide is already available from reputable sources — you just need to know where to look.
Reality
Retatrutide is an unapproved investigational drug. Outside of enrollment in Eli Lilly's TRIUMPH trials, there is no FDA-sanctioned clinical or compounding pathway for obtaining it in the United States. Research-chemical suppliers marketing retatrutide are not operating within any approved framework. Quality, potency, sterility, and exact molecular identity of grey-market product cannot be verified, and acquiring retatrutide from these sources carries real legal and clinical risk beyond the drug itself.
Myth
Retatrutide is just tirzepatide with glucagon added — a minor update.
Reality
Retatrutide is a purpose-designed triple agonist; it is not a combination product or a structural minor variation of tirzepatide. The glucagon-receptor component introduces a distinct mechanism — increased energy expenditure and hepatic fat mobilization — that neither GLP-1 nor GIP agonism produces alone. The clinical consequence is the largest weight loss seen in a Phase 2 obesity trial to date, along with a distinct side-effect and safety profile (modestly elevated heart rate, potential for glycemic excursions) that tirzepatide does not share.
Myth
Because retatrutide produces more weight loss than tirzepatide, it must be better for everyone.
Reality
Weight-loss magnitude is one of several clinically relevant outcomes. Retatrutide's higher efficacy at 12 mg is accompanied by a glucagon-driven heart-rate effect and different tolerability trade-offs that may not suit every patient. Until head-to-head trials are completed and long-term safety data mature, relative ranking for individual patients cannot be determined. For many patients, tirzepatide or semaglutide will remain the optimal choice even after retatrutide is approved.
Myth
Retatrutide will cure obesity — you'll take it for 6–12 months and be done.
Reality
Obesity is a chronic, relapsing condition driven by neuroendocrine biology that reverts when pharmacological signal is removed. Every GLP-1-class drug studied with a discontinuation arm shows substantial weight regain within a year of stopping. Retatrutide is highly likely to behave the same way — no published evidence suggests it produces durable physiologic remodeling that persists after withdrawal. Framing it as a short-term cure misrepresents both the pharmacology and the condition.
Published Research
45 studiesRetatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.
TRIUMPH-1 (Jastreboff et al., NEJM 29 September 2026) — the pivotal Phase 3 obesity trial. 2,339 adults with obesity and no diabetes were randomized to weekly retatrutide 4, 9, or 12 mg or placebo for 80 weeks. Mean weight change was -17.6%, -23.7%, and -25.0% versus -3.9% on placebo (treatment-regimen estimand). Substudies showed reduced knee-osteoarthritis pain (n=574) and fewer apnea-hypopnea events (n=243). The anchor citation for retatrutide's obesity efficacy.
Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.
Bellido et al., Lancet 29 September 2026. 1,152 adults with type 2 diabetes and BMI of 27 or higher, randomized to retatrutide 4, 9, or 12 mg or placebo for 80 weeks. Weight change was -11.9%, -16.8%, and -18.8% versus -5.1% (treatment-regimen estimand). Diarrhea and nausea were the most common adverse events; dysesthesia (4-7% vs 1%) and hypotension (1-6% vs <1%) were more frequent than on placebo, and discontinuation for adverse events or death was 4%, 12%, and 8% versus 5%.
Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis.
Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.
Retatrutide: Obesity drug opens to 'compassionate use' in US after speculation Trump took it.
Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.
Lancet June 2026 — TRANSCEND-T2D-1, the first published Phase 3 retatrutide primary readout, in adults with T2D on diet + exercise alone. The trial that moves retatrutide from Phase 2 + press-release Phase 3 territory into a genuine peer-reviewed Phase 3 evidence base for glycemic and weight outcomes. Anchor citation for any post-2026 assessment of retatrutide's regulatory-quality efficacy data.
Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes
Post-hoc metabolomics and lipidomics analysis of two Phase 2 trials (n=495 combined) showing retatrutide drives changes in fatty-acid oxidation markers (3-hydroxybutyrate, acylcarnitines) and insulin-resistance markers (branched-chain amino acids, 2-aminoadipic acid, urate) — with the acylcarnitine cluster mediating 23.2% of weight reduction in non-T2D participants.
Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review
Multi-omic profiling reveals Retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials
Retatrutide in type 2 diabetes mellitus and obesity: an overview
Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials
The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities
Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis
Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease.
Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study
Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials
Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids
Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial
Retatrutide-A Game Changer in Obesity Pharmacotherapy
Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis
Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials
Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled Trials
Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis
Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis
Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis
Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis
The power of three: Retatrutide's role in modern obesity and diabetes therapy
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials
Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice
Comparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management: Insights From Clinical Trials
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Sanyal et al. (Nat Med 2024): a substudy of the Phase 2 obesity trial in 98 adults with MASLD and at least 10% liver fat on MRI (MRI-PDFF). At 24 weeks, relative liver-fat change was -42.9%, -57.0%, -81.4%, and -82.4% at 1, 4, 8, and 12 mg versus +0.3% on placebo, and 79% (8 mg) and 86% (12 mg) reached normal liver fat (below 5%). No biopsies were taken, so histologic MASH resolution was not assessed.
A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity
Retatrutide showing promise in obesity (and type 2 diabetes)
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Phase 2 trial in 281 adults with type 2 diabetes showing retatrutide reduced HbA1c by up to 2.02% and body weight by up to 16.9% at 36 weeks, outperforming the active comparator dulaglutide on both endpoints.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Landmark Phase 2 NEJM trial (n=338) showing retatrutide achieved up to 24.2% body weight loss at 48 weeks with the 12mg dose — the highest weight loss ever recorded for an obesity drug at that time, establishing retatrutide as the leading candidate in next-generation obesity therapy.
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
First-in-patient Phase 1b trial (n=72) establishing proof of concept for triple agonism, showing dose-dependent reductions in HbA1c (up to 1.56%) and body weight (up to 8.96 kg) over 12 weeks with an acceptable safety profile.
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes (TRIUMPH-2 press release, 29 September 2026)
Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial (TRIUMPH-4 topline, 11 December 2025)
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1 topline, 21 May 2026)
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C (TRIUMPH-2 and TRIUMPH-3 topline, 23 July 2026)
Popular Stacks Including Retatrutide
CagriSema / CagriTriz / CagriReta (Cagrilintide + GLP-1 Agonist)
A family of weekly injectable obesity stacks that pair the long-acting amylin analog cagrilintide with a GLP-1 receptor agonist — semaglutide (CagriSema), tirzepatide (CagriTriz), or retatrutide (CagriReta). Only CagriSema has completed pivotal clinical trials; the other two are conceptual compounded or investigational combinations.
Retatrutide + Tesamorelin
A gray-market pairing of Lilly's unapproved triple agonist retatrutide (or, more often, tirzepatide) with tesamorelin, the FDA-approved GHRH analog for HIV-associated belly fat. The pitch is extra visceral-fat loss and protected muscle. No trial has tested it. Growth hormone works against the incretin's blood-sugar benefit, GLP-1-class drugs already cut visceral fat on their own, and 'tesamorelin preserves lean mass on a GLP-1' is untested.
Quick Facts
- Class
- Triple GIP/GLP-1/Glucagon Receptor Agonist
- Tier
- A
- Evidence
- Moderate
- Safety
- Moderate Data
- Updated
- Oct 2026
- Citations
- 45PubMed
Also known as
Tags
Peptide Families
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.